Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 19/20 | 1.00 |
| ▸ | PLD2 | O14939 | 17/20 | 1.00 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.52 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.52 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845970 | 0.93 | PLD1 (1.00) | PLD1PLD2 | |
| SCHEMBL14845960 | 0.91 | PLD1 (1.00) | PLD1PLD2 | |
| SCHEMBL14845964 | 0.87 | PLD1 (1.00) | PLD1PLD2 | |
| SCHEMBL14845962 | 0.83 | PLD2 (1.00) | PLD1PLD2YEATS4MLLT3MLLT1 | |
| SCHEMBL14845957 | 0.83 | PLD2 (1.00) | PLD1PLD2YEATS4MLLT3MLLT1 | |
| SCHEMBL14845952 | 0.82 | PLD2 (1.00) | PLD1PLD2YEATS4MLLT3MLLT1 | |
| SCHEMBL14846031 | 0.81 | PLD2 (1.00) | PLD1PLD2YEATS4MLLT3MLLT1 | |
| SCHEMBL14846029 | 0.80 | PLD2 (1.00) | PLD1PLD2YEATS4MLLT3MLLT1 | |
| SCHEMBL19579362 | 0.79 | PLD1 (1.00) | PLD1PLD2 | |
| SCHEMBL14845961 | 0.79 | PLD1 (1.00) | PLD1PLD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2014093557-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014093553-A1 | METHODS AND COMPOSITIONS OF TREATING HIV INFECTION | VANDERBILT UNIVERSITY (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2013049773-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | PLD1 1/4885PLD2 2/4885YEATS4 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.